Cytokinetics Announces Heart Failure Program Update SYS-CON Media (press release) Based on the review of these data, the companies have selected oral formulations of omecamtiv mecarbil from this Phase I trial that warrant further evaluation in patients with heart failure. Cytokinetics and Amgen are discussing plans for the ... |
